Skip to content
Relatix Bio

Relatix Bio

Radically different

  • Services
  • Knowledgebase
  • Partnerships
  • Our Approach
  • Contact
  • About
    • Vision
    • Our mission
    • Privacy Policy
    • FAQ
    • News
Posted on July 1, 2026 by admin

A Phase 3 Bridging Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD

Conditions: Attention Deficit Hyperactivity Disorder; Attention-Deficit / Hyperactivity Disorder; ADHD

Interventions: Drug: AK-D101; Drug: Placebo

Sponsors: Alvogen Korea

Not yet recruiting
CategoriesImported News TagsAcademic research, ADHD, Clinical trial, Cognitive focus and executive control, News Approved

Post navigation

Previous PostPrevious Agriculture is ready for AI, but its data isn’t
Next PostNext Effectiveness of a Virtual Reality Social Skills Intervention in Autism

This is the footer

Privacy Policy Proudly powered by WordPress